Tag: ImmunityBio

ImmunityBio is posting its strongest-ever quarterly sales, yet the stock is heading in the opposite direction. The biotech group generated ...

ImmunityBio has pulled off a remarkable feat in the Middle East, getting its immunotherapy ANKTIVA onto the Saudi Arabian market ...

ImmunityBio finds itself navigating a stark dichotomy. While its commercial engine, driven by the cancer drug ANKTIVA, is firing on ...

ImmunityBio finds itself navigating a stark contradiction. While its commercial engine is firing on all cylinders, a brewing legal storm ...

ImmunityBio finds itself navigating a stark dichotomy. While the biotech firm reports its strongest commercial quarter to date, it is ...

ImmunityBio is navigating a stark divide. While its commercial engine, driven by the cancer drug Anktiva, is firing on all ...

ImmunityBio's stock is navigating a volatile path, caught between explosive commercial growth for its bladder cancer drug and a rising ...

The biotechnology firm ImmunityBio finds itself caught between significant operational progress and mounting regulatory scrutiny. A recent official warning from ...

A recent $100 million financing deal has provided a crucial lifeline for ImmunityBio, following a period of significant market volatility ...

Investors in biotechnology firm ImmunityBio are navigating a landscape of stark contrasts. The company's commercial prospects appear increasingly bright, driven ...